WO2015128500A1 - A process for the preparation of group b adenoviruses - Google Patents
A process for the preparation of group b adenoviruses Download PDFInfo
- Publication number
- WO2015128500A1 WO2015128500A1 PCT/EP2015/054219 EP2015054219W WO2015128500A1 WO 2015128500 A1 WO2015128500 A1 WO 2015128500A1 EP 2015054219 W EP2015054219 W EP 2015054219W WO 2015128500 A1 WO2015128500 A1 WO 2015128500A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- cells
- cell
- process according
- adenovirus
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 81
- 230000008569 process Effects 0.000 title claims abstract description 68
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 173
- 241000700605 Viruses Species 0.000 claims abstract description 161
- 238000004519 manufacturing process Methods 0.000 claims abstract description 26
- 238000012258 culturing Methods 0.000 claims abstract description 21
- 230000006037 cell lysis Effects 0.000 claims abstract description 15
- 239000000835 fiber Substances 0.000 claims abstract description 14
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 230000029812 viral genome replication Effects 0.000 claims abstract description 6
- 238000002955 isolation Methods 0.000 claims abstract description 5
- 238000009472 formulation Methods 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims abstract description 3
- 230000010076 replication Effects 0.000 claims description 15
- 238000000746 purification Methods 0.000 claims description 9
- 230000010412 perfusion Effects 0.000 claims description 7
- 230000001464 adherent effect Effects 0.000 claims description 6
- 238000004114 suspension culture Methods 0.000 claims description 6
- 238000011210 chromatographic step Methods 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- 238000004115 adherent culture Methods 0.000 claims description 2
- 238000005571 anion exchange chromatography Methods 0.000 claims description 2
- 210000000234 capsid Anatomy 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 description 44
- 208000015181 infectious disease Diseases 0.000 description 43
- 239000002245 particle Substances 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 30
- 230000003612 virological effect Effects 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 23
- 244000309459 oncolytic virus Species 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 229950002830 enadenotucirev Drugs 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 11
- 230000000174 oncolytic effect Effects 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 239000008188 pellet Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 9
- 230000009089 cytolysis Effects 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000011194 good manufacturing practice Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 230000002950 deficient Effects 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 108091092356 cellular DNA Proteins 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000011143 downstream manufacturing Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000010268 HPLC based assay Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 0 C*C(C(C)C(C)(C(C)C*C(C)*(C*)**C=C)C1NC*)C1=C Chemical compound C*C(C(C)C(C)(C(C)C*C(C)*(C*)**C=C)C1NC*)C1=C 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 101710094396 Hexon protein Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 241001068263 Replication competent viruses Species 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000013017 sartobind Substances 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 description 1
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 description 1
- 241000182988 Assa Species 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101150005585 E3 gene Proteins 0.000 description 1
- 101150066038 E4 gene Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 101150032643 IVa2 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101710173835 Penton protein Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101710109576 Terminal protein Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 239000003014 ion exchange membrane Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Definitions
- the present disclosure relates to a method for the manufacture of certain group B adenoviruses, in particular replication competent adenoviruses, and the viral product obtained therefrom.
- EnAd previously known as
- ColoAdl is a chimeric oncolytic adenovirus (WO 2005/118825) currently in clinical trials for the treatment of colorectal cancer.
- adenoviral based therapeutic agents need to be manufactured in quantities suitable for supporting both the clinical trials and demand after registration and under conditions that adhere to good manufacturing practice (GMP).
- the viruses are propagated in mammalian cells in vitro, for example in a cell suspension culture.
- the virus is recovered from these cells by cell lysis and subsequent purification.
- Figure 1 is an extract from Kamen & Henry 2004 (J Gene Med. 6: pages 184-192) showing a schematic diagram of the processes involved manufacture of the GMP grade adenovirus.
- the cells are lysed.
- Contaminating DNA from the cells after lysis is a significant problem and must be removed as far as possible from the therapeutic adenoviral product. This is described in detail in the application WO 2011/045381, which describes lysing the cells, fragmenting or precipitating the DNA within the cell suspension and clarifying the same, employing tangential flow. DNA digestion with DNAse is also shown as the third step in Figure 1.
- type B adenovirus can be prepared by a process that isolates the virus from the cell media and that avoids the necessity to lyse the cells and thus significantly reduces the starting level of DNA contamination in the viral product.
- adenovirus having a fibre and hexon of subgroup B such as Adll, in particular Adllp also known as the Slobitski strain
- Adll in particular Adllp also known as the Slobitski strain
- step b. at the end of the culturing period isolating from the media the virus from step a) by filtering wherein the isolation of virus is not subsequent to a cell lysis step.
- adenovirus having a fibre and hexon of subgroup B such as Adll, in particular Adllp also known as the Slobitski strain
- Adll in particular Adllp also known as the Slobitski strain
- said process comprises the steps:
- the virus is other than a chimeric oncolytic adenovirus having a genome comprising an E2B region, wherein said E2B region comprises a nucleic acid sequence from a first adenoviral serotype and a nucleic acid sequence from a second distinct adenoviral serotype; wherein said first and second serotypes are each independently selected from the adenoviral subgroups B, C, D, E, F or G.
- the virus is replication competent or replication deficient, such as replication competent.
- the adenovirus has part or all of the E3 region deleted.
- the present processes extends to wild-type group B viruses, for example Adll viruses, such as Adllp, and also to viruses having a fibre and hexon from Adll, including Adllp.
- Adll viruses such as Adllp
- Adllp viruses having a fibre and hexon from Adll, including Adllp.
- Figure 1 Is an extract from Kamen and Henry 2004 (J Gene Med. 6: S184-192) showing a schematic diagram of the processes involved manufacture of the GMP grade adenovirus.
- Figure 2 shows the proportion of infectious ColoAdl particles associated with the cells
- Figure 3 shows the proportion of infectious ColoAdl particles associated with the cells
- Figure 4 shows total viral particle amounts of suspension HEK293 culture in an assay testing
- Figure 8 A - Virus distribution (CVL or supernatant)
- Adenovirus as employed will generally refer to a replication competent adenovirus or replication deficient, for example a group B virus, in particular Adll, such as Adllp, unless the context indicates otherwise. In some instances it may be employed to refer only to replication competent viruses and this will be clear from the context.
- Adenovirus vector will generally refer to a replication deficient adenovirus.
- Subgroup B refers to viruses with at least the fibre and hexon from a group B adenovirus, for example the whole capsid from a group B virus, such as substantially the whole genome from a group B virus.
- Enadenotucirev is a chimeric oncolytic adenovirus, formerly known as EnAd (WO2005/118825), with fibre, penton and hexon from Adllp, hence it is a subgroup B virus. It has a chimeric E2B region, which comprises DNA from Adllp and Ad3. Almost all of the E3 region and part of the E4 region is deleted in EnAd.
- a process for the manufacture of an adenovirus as employed herein is intended to refer to a process wherein the virus is replicated and thus the number of viral particles is increased.
- the manufacturing is to provide sufficient numbers of viral particles to formulate a therapeutic product, for example in the range 1-9 x 10 s to 1-9 x 10 20 or more particles may be produced, such as in the range of 1-9 xlO 8 to 1-9 xlO 15 viral particles, in particular 1 to 9 xlO 10 or 1-9 x 10 15 viral particles may be produced from a 10L batch.
- Part of the E3 region is deleted (partly deleted in the E3 region) as employed herein refers to at least part, for example in the range 1 to 99% of the E3 region is deleted, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94 95, 96, 97 or 98% deleted, for example in a coding and/or non-coding region of the gene.
- Completely deleted (also referred to herein as wholly deleted) in the E3 region means the coding part of the gene is completed deleted. In one embodiment the coding and non-coding part of the gene is deleted.
- E3 refers to the DNA sequence encoding part or all of an adenovirus E3 region (i.e. protein/polypeptide), it may be mutated such that the protein encoded by the E3 gene has conservative or non-conservative amino acid changes, such that it has the same function as wild-type (the corresponding unmutated protein); increased function in comparison to wild-type protein; decreased function, such as no function in comparison to wild-type protein or has a new function in comparison to wild-type protein or a combination of the same, as appropriate.
- adenovirus E3 region i.e. protein/polypeptide
- the viruses of the present disclosure are not partly deleted in the E4 region.
- the Eorf4 is not deleted.
- Part of the E4 region is deleted (partly deleted in the E4 region) as employed herein means that at least part, for example in the range 1 to 99% of the E4 region is deleted, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94 95, 96, 97 or 98% deleted.
- Completely present in the E4 region means the E4 is 100% present i.e. nothing is removed. Having said that the gene may be: mutated wherein up to 10% of the base pairs are replaced (but not deleted); or be interrupted, for example the E4 region may be interrupted by a transgene. Thus 100% complete as employed herein means 100% present in the relevant location in the genome, however the gene many be contiguous or non-contiguous.
- Completely deleted (also referred to herein as wholly deleted) in the E4 region means the coding part of the gene is completed deleted. In one embodiment the coding and non-coding part of the gene is deleted.
- E4 refers to the DNA sequence encoding an adenovirus E4 region (i.e.
- polypeptide/protein region which may be mutated such that the protein encoded by the E4 gene has conservative or non-conservative amino acid changes, and has the same function as wild-type (the corresponding non-mutated protein); increased function in comparison to wild-type protein; decreased function, such as no function in comparison to wild-type protein or has a new function in comparison to wild-type protein or a combination of the same as appropriate.
- the E4 region may have some function or functions relevant to viral replication and thus modifications, such as deletion of the E4 region may impact on a virus life-cycle and replication, for example such that a packaging cell may be required for replication.
- “Derived from” as employed herein refers to, for example where a DNA fragment is taken from an adenovirus or corresponds to a sequence originally found in an adenovirus. This language is not intended to limit how the sequence was obtained, for example a sequence employed in a virus according to the present disclosure may be synthesised.
- the derivative has 100% sequence identity over its full length to the original
- the derivative has 95, 96, 97, 98 or 99% identity or similarity to the original DNA sequence.
- the derivative hybridises under stringent conditions to the original DNA sequence.
- stringency typically occurs in a range from about Tm (melting temperature)- 50°C (5° below the Tm of the probe) to about 20°C to 25°C below Tm.-
- Tm melting temperature
- 50°C 50° below the Tm of the probe
- a stringent hybridization can be used to identify or detect identical polynucleotide sequences or to identify or detect similar or related polynucleotide sequences.
- stringent conditions means hybridization will generally occur if there is at least 95%, such as at least 97% identity between the sequences.
- hybridization shall include “any process by which a polynucleotide strand joins with a complementary strand through base pairing” (Coombs, J., Dictionary of Biotechnology, Stockton Press, New York, N.Y., 1994). Wherein the isolation is not subsequent to a cell lysis step" as employed herein is intended to refer to the fact the manufacturing process does not comprise a specific lysis step.
- a step where the conditions are designed to lyse all or most of the cells in the culture for example does not employ a chemical lysis step, an enzymatic lysis step, a lysis buffer step, a mechanical lysis step or a physical lysis step such as centrifuging or freeze-thawing.
- Conditions of the culture that ultimately stress all the cells such that they die and lyse, for example starving the cells to death under batch culture conditions will be considered a specific lysis step in the context of the present specification.
- Most as employed herein refers to a large majority, for example 50% or more such as 80, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%.
- At the end of the culturing period refers to at the end of a period over which the virus in the infected cells has been allowed to replicate. End refers to a selected point in time selected for harvesting. End as employed herein is not definitive end-point. In one embodiment the end- point is chosen to follow a sufficient period of cultivation for the replicated virus or a significant proportion thereof to be released into the medium or supernatant. In one embodiment the harvesting occurs at multiple time points or is ongoing after it is initiated.
- the present process may simplify downstream processing of the virus because of the lower starting concentration of contaminating DNA from the cells because a cell lysis step is avoided. This may result in cost savings because reagents, equipment and time employed in downstream processing may be reduced. It may also result in greater purity with lower end concentrations of contaminating DNA and/or a lower concentration of large fragments of contaminating DNA.
- virus exposure to cell enzymes is minimised by avoiding cell lysis, which minimises the exposure of the virus to potential degradants, such as nucleases from the cell. This may result in higher virus stability and/or potency as measured, for example by infectivity.
- benzonase to degrade cellular DNA may also be avoided or reduced if desired, which may be advantageous. In particular, removal of the benzonase and testing to show the absence of residual benzonase can be avoided.
- the virus of the present disclosure does not adhere to the cells and so can be readily recovered from the supernatant. This may be a phenomenon which is characteristic of the viruses described herein which facilitates the current process.
- wild-type Ad5 is thought to adhere to cells.
- results have shown that substantially no wild-type Ad5, viral particles are present in the supernatant (see Figure 7 & table 6).
- viruses of the present disclosure further comprise a transgene.
- the lack of adherence to the cells may be related to the hexon and fibre of the virus.
- Oncolytic viruses are those which preferentially infect cancer cells and hasten cell death, for example by lysis of same, or selectively replicate in the cancer cells.
- Viruses which preferentially infect cancer cells are viruses which show a higher rate of infecting cancer cells when compared to normal healthy cells.
- the virus of the present disclosure is chimeric, for example comprises genomic sequence from at least two adenovirus subgroups excluding subgroup A which is thought to be cancer causing. In one embodiment the chimeric adenoviruses of the present disclosure are not chimeric in the E2B region.
- a adenoviruses such as chimeric adenovirus can be evaluated for its preference for a specific tumor type by examination of its lytic potential in a panel of tumor cells, for example colon tumor cell lines include HT-29, DLD-1, LS174T, LS1034, SW403, HCT116, SW48, and Colo320DM. Any available colon tumor cell lines would be equally useful for such an evaluation.
- Prostate cell lines include DU145 and PC-3 cells.
- Pancreatic cell lines include Panc-1 cells.
- Breast tumor cell lines include MDA231 cell line and ovarian cell lines include the OVCA -3 cell line.
- Hemopoietic cell lines include, but are not limited to, the Raji and Daudi B-lymphoid cells, K562 erythroblastoid cells, U937 myeloid cells, and HSB2 T-lymphoid cells. Other available tumor cell lines are equally useful.
- a virus of the present disclosure is oncolytic.
- Oncolytic viruses including those which are non-chimeric (i.e. oncolytic viruses may be chimeric or non-chimeric), for example Adll, such as Adllp can similarly be evaluated in these cell lines and has oncolytic activity.
- Viruses which selectively replicate in cancer cells are those which require a gene or protein which is upregulated in a cancer cell to replicate, such as a p53 gene.
- the oncolytic virus of the present disclosure is apoptotic, that is hastens programmed cell death.
- the oncolytic virus of the present disclosure is cytolytic.
- the cytolytic activity of chimeric oncolytic adenoviruses of the disclosure can be determined in representative tumor cell lines and the data converted to a measurement of potency, for example with an adenovirus belonging to subgroup C, preferably Ad5, being used as a standard (i.e. given a potency of 1).
- a suitable method for determining cytolytic activity is an MTS assay (see Example 4, Figure 2 of WO 2005/118825 incorporated herein by reference).
- the oncolytic adenovirus of the present disclosure causes cell necrosis.
- the chimeric oncolytic virus has an enhanced therapeutic index for cancer cells.
- Therapeutic index or “therapeutic window” refers to a number indicating the oncolytic potential of a given adenovirus which may be determined by dividing the potency of an oncolytic adenovirus of the present disclosure in a relevant cancer cell line by the potency of the same adenovirus in a normal (i.e. non-cancerous) cell line.
- the oncolytic virus has an enhanced therapeutic index in one or more cancer cells selected from the group comprising colon cancer cells, breast cancer cells, head and neck cancers, pancreatic cancer cells, ovarian cancer cells, hemopoietic tumor cells, leukemic cells, glioma cells, prostate cancer cells, lung cancer cells, melanoma cells, sarcoma cells, liver cancer cells, renal cancer cells, bladder cancer cells and metastatic cancer cells.
- cancer cells selected from the group comprising colon cancer cells, breast cancer cells, head and neck cancers, pancreatic cancer cells, ovarian cancer cells, hemopoietic tumor cells, leukemic cells, glioma cells, prostate cancer cells, lung cancer cells, melanoma cells, sarcoma cells, liver cancer cells, renal cancer cells, bladder cancer cells and metastatic cancer cells.
- Table 1 shows the adenovirus serotypes:
- the E2B region is a known region in adenoviruses and represents about 18% of the viral genome. It is thought to encode protein IVa2, DNA polymerase and terminal protein. In the Slobitski strain of Adll (referred to as Adllp) these proteins are encoded at positions 5588-3964, 8435-5067 and 10342-8438 respectively in the genomic sequence and the E2B region runs from 10342-3950. The exact position of the E2B region may change in other serotypes but the function is conserved in all human adenovirus genomes examined to date as they all have the same general organisation.
- the virus of the present disclosure such as an oncolytic virus has a subgroup B hexon.
- the virus of the disclosure such as an oncolytic virus has an Adll hexon, such as an Allp hexon.
- the virus of the disclosure such as an oncolytic virus has a subgroup B fibre.
- the virus of the disclosure such as an oncolytic virus has an Adll fibre, such as an Allp fibre.
- the virus of the disclosure such as an oncolytic virus has fibre and hexon proteins from the same serotype, for example a subgroup B adenovirus, such as Adll, in particular Adllp.
- the virus of the disclosure such as an oncolytic virus has fibre, hexon and penton proteins from the same serotype, for example Adll, in particular Adllp, for example found at positions 30811-31788, 18254-21100 and 13682-15367 of the genomic sequence of the latter.
- a virus of a distinct serotype to a first virus may be from the same subgroup or a different subgroup but will always be from a different serotype.
- the combinations are as follows in (first Ad serotype: second Ad serotype): AA, AB, AC, AD, AE, AF, AG, BB, BC, BD, BF, BG, CC, CD, CE, CF, CG, DD, DE, DF, DG, EE, EF, EG, FF, FG and GG.
- Mammalian cells are cell derived from a mammal.
- the mammalian cells are selected from the group comprising HEK, CHO, COS-7, HeLa, Viro, A549, PerC6 and GM K, in particular H EK293.
- Replication deficient viruses of the present disclosure require a packaging cell line to replicate.
- Packaging cell lines contain a gene or genes to complement those which are deficient in the virus.
- the cells are grown in adherent or suspension culture, in particular a suspension culture.
- Culturing mammalian cells as employed herein refers to the process where cells are grown under controlled conditions ex vivo. Suitable conditions are known to those in the art and may include temperatures such as 37°C. The C0 2 levels may need to be controlled, for example kept at a level of 5%.
- the cells will be cultured to generate sufficient numbers before infection with the adenovirus. These methods are known to those skilled in the art or are readily available in published protocols or the literature.
- the cells will be cultured on a commercial scale, for example 5L, 10L, 15L, 20L, 25L,
- EX-CELL ® media from Sigma-Aldrich, such as EX-CELL ® 293 serum free medium for HEK293 cells, EX-CELL ® ACF CHO media serum free media for CHO cells, EX-CELL ® 302 serum free media for CHO cells, EX-CELL CD hydrolysate fusion media supplement, from Lonza RMPI (such as RMPI 1640 with HEPES and L-glutamine, RMPI 1640 with or without L-glutamine, and RMPI 1640 with UltraGlutamine), MEM and DMEM, SFMII medium.
- Lonza RMPI such as RMPI 1640 with HEPES and L-glutamine, RMPI 1640 with or without L-glutamine, and RMPI 1640 with UltraGlutamine
- MEM and DMEM SFMII medium.
- the medium is serum free. This is advantageous because it facilitates registration of the manufacturing process with the regulatory authorities.
- viruses of the present disclosure such as oncolytic viruses have different properties to those of adenoviruses used as vectors such as Ad5, this includes the fact that they can be recovered from the medium without the need for cell lysis. Thus, whilst not wishing to be bound by theory, the viruses appear to have mechanisms to exit the cell.
- group viruses employed in the method of the present disclosure appear much earlier in the supernatant than group C adenoviruses, in particular Ad5, under corresponding conditions.
- viruses employed in the method of the present disclosure are available in the supernatant at a given time point, for example in the range of 30 to 100 hours at levels which exceed the levels of achieved for group C viruses, such as Ad5 under corresponding conditions.
- viruses of the present disclosure such as oncolytic adenoviruses do not seem to associate or adhere the cells after exiting the same, which also facilitates recovery from the supernatant, in particular when the cell culturing conditions are optimised.
- viruses of the present disclosure do not appear to degrade, even when the culturing process is extended to 70 hours or more.
- the degradation of the virus can be checked by assaying the infectivity of the virus.
- the infectivity of the virus decreases as the viral particles degrade.
- the culturing period is in the range 30 to 100 hours, for example 35 to 70 hours, for example 40, 45, 50, 55, 60 or 65 hours.
- the culturing period is 65, 70, 75, 80, 85, 90, 95 hours or more.
- the culturing period is in the range 60 to 96 hours.
- adenovirus is present in the supernatant at the 64 hour time point, for example, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100%, such as 95% or more, particularly 98% or more.
- significant amounts of virus are in media post 38 hours. For example, over 50%, particularly over 70% of the virus is in the media post 38 hours.
- the maximum total virus production is achieved at about 40 to 60 hours post-infection, for example 49 hours post-infection. In one embodiment the decrease in virus production following the maximum is slow.
- the maximum total virus production is achieved at about 60 to 96 hours, for example 70 to 90 hours post-infection.
- the present inventors have found that, when employing the process, the cells maintain high viability (such as 80 to 90% viability) post-infection for over 90 hours.
- the harvesting and process may continue as long as the cells remain viable.
- Maximum total virus production as employed herein means the total number of viral particles produced per cell and encompasses viral particles in the supernatant and the cell.
- virus production in the supernatant at 49 hours post-infection is about
- vp/cell 20000 to 30000 viral particles per cell
- vp/cell 20000 to 30000 viral particles per cell
- Example 6 describes how the CVL was obtained.
- CVL as employed herein means the crude viral lysate.
- Culturing cells may employ a perfusion culture, fed batch culture, batch culture, a steady state culture, a continuous culture or a combination of one or more of the same as technically appropriate, in particular a perfusion culture.
- the process is a perfusion process, for example a continuous perfusion process.
- the culture process comprises one or more media changes. This may be beneficial for optimising cell growth, yield or similar. Where a medium change is employed, it may be necessary to recover virus particle from the media being changed. These particles can be combined with the main virus batch to ensure the yield of virus is optimised. Similar techniques may also be employed with the medium of a perfusion process to optimise virus recovery.
- the culture process does not include a medium change step. This may be advantageous because no viral particles will be lost and therefore yield may be optimised.
- the culture process comprises one or more cell additions or changes.
- Cell addition as employed herein refers to replenishing some or all of the cells and change refers to removing dead cells and adding new cells (not necessarily in that order).
- the adenovirus during culture is at concentration in the range 20 to 150 particles per cell (ppc), such as 40 to 100 ppc, in particular 50ppc.
- ppc particles per cell
- virus concentrations such as less than lOOppc, in particular 50ppc may be advantageous because this may result in increased cell viability compared to cultures with higher virus concentrations, particularly when cell viability is measured before harvesting.
- cell viability is around 80 to 95% during the process, for example at the 96 hour time point (i.e. 96 hours post-infection) when infected with virus, such as 83 to 90% viability.
- cell viability is around 80 to 90% during the process, for example at the 96 hour time point (i.e. 96 hours post-infection) when infected with Adll. For example 85% viability.
- the medium and/or cells are supplements or replenished periodically.
- the cells are harvested during the process, for example at a discrete time point or time points or continuously.
- harvesting the virus is performed at a time point selected from about 40,
- the mammalian cells are infected with a starting concentration of virus of 1-9 x 10 4 vp/ml or greater, such as 1-9 x 10 s , 1-9 x 10 s , 1-9 x 10 7 , 1-9 x 10 s , 1-9 x 10 9 , in particular 1-5 x 10 s vp/ml or 2.5-5 x 10 s vp/ml.
- the mammalian cells are infected at a starting concentration of 1x10 s cells/ml at about 1 to 200ppc, for example 40 to 120ppc, such as 50ppc.
- Ppc as employed herein refers to the number of viral particles per cell. In one embodiment the process is run at about 35 to 39°C, for example 37°C.
- the process run at about 4-6% C0 2 , for example 5% CO2.
- the media containing the virus such as the chimeric oncolytic viral particles is filtered to remove the cells and provide crude supernatant for further downstream processing.
- a tangential flow filter is employed.
- medium is filtered employing Millipore's Millistak+ ® POD system with cellulose based depth filters.
- Millistak+ ® depth filter medium is offered in a scalable, disposable format, the Pod Filter System. It is ideal for a wide variety of primary and secondary clarification applications, including cell cultures.
- Millistak+ ® Pod filters are available in three distinct series of media grades in order to meet specific application needs. Millistak+ ® DE, CE and HC media deliver optimal performance through gradient density matrix as well as positive surface charge properties.
- the filtration is effected using tangential flow technology, for example employing the CogentTM M system comprising a Pellicon Mini cassette membrane holder, pressure sensors, 10 litre recycle tank with mixer, retentate flow meter, weigh scale, feed pump, transfer pump, piping and valves. Control and operation of the system is manual with an exception of semi-automatic diafiltration/concentration. The operator has manual control of pump speeds, all valves and operational procedures.
- the virus can also, if desired, be formulated into the final buffer in this step.
- concentrated and conditioned adenovirus material is provided in a final or near final formulation.
- the process comprises two or more filtration steps.
- downstream processing comprises Millistak+POD system 35 CE and 50 CE cassettes followed by an opticap XL 10 express 0.5/0.2 um membrane filter in series.
- the process further comprises a purification step, selected from a CsCI gradient, chromatography step (such as size exclusion chromatography), ion-exchange chromatography (in particular anion-exchange chromatography) and a combination thereof.
- a purification step selected from a CsCI gradient, chromatography step (such as size exclusion chromatography), ion-exchange chromatography (in particular anion-exchange chromatography) and a combination thereof.
- Ion exchange chromatography binds DNA very strongly and typically is the place were any residual DNA is removed.
- the ion exchange resin/membrane binds both the virus and the DNA and during salt gradient elusion the virus normally elutes off the column first (low salt gradient) and the DNA is eluted at a much higher salt concentration since the interaction of the DNA with the resin is stronger than the virus.
- the chromatography step or steps employ monolith technology, for example available from BIA Separations.
- Sartobind Q (quaternary amine membrane purification process) is employed as a purification step.
- Source Q RESIN is employed in a purification step.
- Sartobind Q is employed followed by Source Q RESIN in downstream processing of the isolated virus.
- Source Q is employed in the purification step.
- the virus prepared contains less than 80ng/mL of contaminating DNA, for example between 60ng/mL and lOng/mL.
- substantially all the contaminating DNA fragments are 700 base pairs or less, for example 500bp or less, such as 200bp or less.
- residual benzonase content in the purified virus product is Ing/mL or less, such as 0.5ng/mL or less.
- the residual host cell protein content in the purified virus product in 20ng/mL or less, for example 15ng/mL or less, in particular when measured by an ELISA assay.
- residual tween in the purified virus product is O.lmg/mL or less, such as
- the virus has a hexon and fibre from a group B adenovirus, for example
- isolated purified group B adenovirus according to the present disclosure wherein the contaminating DNA content is less than 80ng/mL.
- the virus is replication competent.
- Replication competent virus as employed herein refers to a virus that is capable of replication without the assistance of a complementary cell line encoding an essential viral protein, such as that encoded by the El region (also referred to as a packaging cell line) and virus capable of replicating without the assistance of a helper virus.
- Viral vectors are replication deficient and require a packaging cell to provide a complementary gene to allow replication.
- the virus of the disclosure such as an oncolytic virus of the present disclosure comprises one or more transgenes, for example one or more transgenes encoding therapeutic peptide(s) or protein sequence(s).
- a virus such as an oncolytic virus encodes at least one transgene.
- Suitable transgenes include so called suicide genes such as p53; polynucleotide sequences encoding cytokines such as IL-2, IL-6, IL-7, IL-12, IL-15, IL-18, IL-21, GM-CSF or G-CSF, an interferon (eg interferon I such as IFN-alpha or beta, interfon II such as IFN-gamma), a TNF (eg TNF-alpha or TNF-beta), TGF-beta, CD22, CD27, CD30, CD40, CD120; a polynucleotide encoding a monoclonal antibody, for example trastuzamab, cetuximab, panitumumab, pertuzumab, epratuzumab, an anti-EGF antibody, an anti-VEGF antibody and anti-PDGF antibody, an anti-FGF
- transgenes encode molecules that themselves act to modulate tumour or immune responses and act therapeutically, or are agents that directly or indirectly inhibit, activate or enhance the activity of such molecules.
- Such molecules include protein ligands or active binding fragments of ligands, antibodies (full length or fragments, such as Fv, ScFv, Fab, F(ab)'2 or smaller specific binding fragments), or other target-specific binding proteins or peptides (e.g. as may be selected by techniques such as phage display etc), natural or synthetic binding receptors, ligands or fragments, specific molecules regulating the transcription or translation of genes encoding the targets (e.g. siRNA or shRNA molecules, transcription factors).
- Molecules may be in the form of fusion proteins with other peptide sequences to enhance their activity, stability, specificity etc (e.g. ligands may be fused with immunoglobulin Fc regions to form dimers and enhance stability, fused to antibodies or antibody fragments having specificity to antigen presenting cells such as dendritic cells (e.g. anti-DEC-205, anti-mannose receptor, anti-dectin).
- Transgenes may also encode reporter genes that can be used, for example, for detection of cells infected with the "insert- bearing adenovirus", imaging of tumours or draining lymphatics and lymph nodes etc.
- the cancer cell infected with an oncolytic virus is lysed releasing the contents of the cell which may include the protein encoded by a transgene.
- 40 to 93% or more of the total virus replicated in the cells is recoverable from the media, for example 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 or 92% of the total virus is recoverable, such as 94, 95, 96, 97, 98, 99 or 100% of the total virus recoverable.
- the process is a GMP manufacturing process, such as a cGMP manufacturing process.
- the process further comprises the step formulating the virus in a buffer suitable for storage.
- the present disclosure extends to virus or viral formulations obtained or obtainable from the present method.
- lysis buffer pH 8.0
- detergent e.g. 1% Tween-20
- Cell lysis is performed without pH or p0 2 controls. Rocking and heating are used. Lysis is continued for 1.5-2 hours.
- Freeze-thawing multiple times is also a routine method of cell lysis. Pulmozyme may also be employed in cell lysis. Alternative methods for cell lysis include centrifuging cell suspension at 1000 x g, 10 min at 4 °C. Resuspending the cell pellet into 1 ml of Ex-Cell medium 5 % glycerol and releasing the viruses from the cells by freeze-thaw by freezing tubes containing the responded cells from the pellet in liquid nitrogen for 3 - 5 minutes and thaw at +37°C water bath until thawed. Generally the freeze and thaw step is repeated twice more. This cycle releases viruses from the cells. After the last thaw step remove the cell debris by centrifugation 1936 x g, 20 min at +4 °C.
- Benzonase (Merck), 100 U/ml, is used to digest host cell DNA. Benzonase treatment is done for 30 min in +37 °C. Benzonase is stopped with high salt incubation for 1 hour at RT.
- Example 3 EnAd cultured in a HEK 293 suspension culture
- Two virus dilutions 50 and 100 particles per cell
- six harvesting time points 40, 43, 36, 49, 64, and
- Example 4 En Ad cultured in adherent HEK 293 cells
- Adherent HEK293 cells were seeded at 4.8 x lOe cells per flask in 185 crri2 cell culture flasks (24 pieces) 72 hours prior to infection.
- Cell culturing was performed using DMEM - 10% FBS - 2 mM L-glutamine at +37 °C and 5% CO2.
- Cell number was counted from one cell culture flask on the day of infection resulting 40.6 x 10 s cells / flask.
- the tested particles per cell (ppc) were 200, 100 and 50. After infection the cells may be cultured for between 35 to 70 hours.
- Example 5 Visualisation of cellular and viral DNA in the cell lysate (Lysate) or supernatant (SN) of EnAd infected HEK293 cells at 40hrs, 46hrs and 70hrs post-infection.
- HEK293 cells infected with EnAd at 50 particles per cell were harvested 40 hours, 46 hours or 70 hours post-infection.
- the culture supernatants and the cell lysates were collected and total DNA extracted.
- Equivalent volumes of purified lysate or supernatant DNA were loaded in duplicate onto a 0.7% agarose gel and the DNA was separated electrophoresis.
- Significant cellular DNA could be detected at the top of the gel and as a smear in all lanes containing DNA extracted from cell lysates, however only very low levels of cellular DNA could be detected in lanes containing DNA extracted from supernatant (SN).
- viral DNA could be detected in all samples and the total detectable viral DNA observably increased in the supernatant over time. Results are shown in Figure 5.
- EnAd and Adllp were compared for the relative levels of expression of virus particles associated with the cell pellet (CVL) or in the supernatant.
- Suspension HEK293 cells (293f) were cultured in duplicate shaker flasks containing 40 ml working volume of SFMII media supplemented with 4 mM L-glutamine and 50 ⁇ g/ml/50 lU/ml
- the cell expansion was started by thawing one vial of cells and continued cell expansion for 3 weeks until a total of 4.8 x 10 s cells required for this study was achieved.
- the HEK 293 suspension cells were seeded in a single one litre shaker flask using 4 x 10 s cells/ml in 428 ml of SFMII medium per flask (3.4 x 10 s cells/ flask) and incubated in a shaker incubator at + 37°C, 5 % CO2 &115 rpm.
- HEK 293 suspension cells were infected with one of the four different viruses (see Table 5 ) at 50 ppc in duplicate.
- the cells were centrifuged at 1000 x g, 10 min at 4 °C
- the cell pellet was suspended in 1ml of SFMII medium containing 5% glycerol,
- Intracellular virus was released from the cells by freeze-thaw as follows:
- centrifuge tubes were frozen in liquid nitrogen for 3-5 minutes and then transferred to a water bath set at +37°C until thawed.
- step a The freeze and thaw process was repeated twice more as described in step a, above.
- the cell debris is removed from the crude viral lysate (CVL) by centrifugation at 1936 x g for 20 min at +4°C and transfer of the supernatant (CVL) to a new container.
- the CVL was aliquoted as 100 ⁇ samples and stored at -80°C until analysis.
- vp Total viral particle concentration (vp) from Crude Viral Lysate (CVL) and supernatant (SN) samples were analysed by AEX-HPLC assay. These values were then used to calculate the total number of virus particles per culture and the percentage in the SN and CVL for each sample time point. These are represented as bar graphs, together with the viability of the HEK293 cells, for ColoAdl, Ad5 and Allp in Figs 6-8 respectively. For ColoAdl and Adllp the majority of virus was in the culture supernatant whereas for Ad5 virus was entirely in the cell lysate (CVL), being undetectable in the supernatant. For all cultures, the viability of the HEK293 cells remained high over the 96 hours of culture.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present disclosure relates to a process for the manufacture of adenovirus having a fibre and hexon of subgroup B (such as Ad11, in particular Ad11p also known as the Slobitski strain) wherein the E4 region completely present or completely deleted said process comprises the steps: a. culturing mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and b. at the end of the culturing period isolating from the media the virus from step a) by filtering wherein the isolation of virus is not subsequent to a cell lysis step. The disclosure also extends to formulations and viruses obtained from the process.
Description
A Process for the Preparation of Group B Adenoviruses
The present disclosure relates to a method for the manufacture of certain group B adenoviruses, in particular replication competent adenoviruses, and the viral product obtained therefrom.
Background
At the present time the pharmaceutical field is on the edge of realising the potential of viruses as therapeutics for human use. To date a virus derived from ONXY-15 (ONYX Pharmaceuticals and acquired by Shanghai Sunway Biotech) is approved for use in head and neck cancer in a limited number of countries. However, there are a number of viruses currently in the clinic, which should hopefully result in some of these being registered for use in humans.
A number of virus therapies are based on adenoviruses, for example EnAd (previously known as
ColoAdl) is a chimeric oncolytic adenovirus (WO 2005/118825) currently in clinical trials for the treatment of colorectal cancer.
These adenoviral based therapeutic agents need to be manufactured in quantities suitable for supporting both the clinical trials and demand after registration and under conditions that adhere to good manufacturing practice (GMP).
As part of the manufacturing process, the viruses are propagated in mammalian cells in vitro, for example in a cell suspension culture. The virus is recovered from these cells by cell lysis and subsequent purification. Figure 1 is an extract from Kamen & Henry 2004 (J Gene Med. 6: pages 184-192) showing a schematic diagram of the processes involved manufacture of the GMP grade adenovirus. Notably, after viral replication, the cells are lysed.
Contaminating DNA from the cells after lysis is a significant problem and must be removed as far as possible from the therapeutic adenoviral product. This is described in detail in the application WO 2011/045381, which describes lysing the cells, fragmenting or precipitating the DNA within the cell suspension and clarifying the same, employing tangential flow. DNA digestion with DNAse is also shown as the third step in Figure 1.
Much of the work in the field of GMP manufacture of adenoviruses has been performed on Ad5. The prior art indicates that for a batch process a maximum virus titre is achieved around 40 hours post infection and thereafter cell death starts to occur. Furthermore, concerns about reduction in viral infectivity, which is a measure of the activity of the virus produced, are usually addressed by keeping processing times to a minimum in any GMP process.
In short, developing a successful recombinant adenovirus process requires a detailed understanding of basic host cell line physiology and metabolism; the recombinant virus, and the interaction between the cell line and the virus. Essentially the process requires adaptation depending on the particular type of virus or viral vector.
Surprisingly the present inventors have established that type B adenovirus can be prepared by a process that isolates the virus from the cell media and that avoids the necessity to lyse the cells and thus significantly reduces the starting level of DNA contamination in the viral product.
Summary of the Invention
Thus the present disclosure provides a process for the manufacture of adenovirus having a fibre
and hexon of subgroup B (such as Adll, in particular Adllp also known as the Slobitski strain) wherein the E4 region completely present or completely deleted said process comprises the steps:
a. culturing mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and
b. at the end of the culturing period isolating from the media the virus from step a) by filtering wherein the isolation of virus is not subsequent to a cell lysis step.
In one embodiment there is provided a processes according to the present disclosure where the virus does not comprise a E2B region as shown in SEQ ID NO: 1.
Also provided is a process for the manufacture of adenovirus having a fibre and hexon of subgroup B (such as Adll, in particular Adllp also known as the Slobitski strain) wherein the E4 region is completely present or is wholly deleted said process comprises the steps:
a) culturing mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and
b) at the end of the culturing period isolating from the media the virus from step a) by filtering wherein the isolation of virus is not subsequent to a cell lysis step
with the proviso that the virus is other than a chimeric oncolytic adenovirus having a genome comprising an E2B region, wherein said E2B region comprises a nucleic acid sequence from a first adenoviral serotype and a nucleic acid sequence from a second distinct adenoviral serotype; wherein said first and second serotypes are each independently selected from the adenoviral subgroups B, C, D, E, F or G.
In one embodiment the virus is replication competent or replication deficient, such as replication competent.
In one embodiment the adenovirus has part or all of the E3 region deleted.
The present processes extends to wild-type group B viruses, for example Adll viruses, such as Adllp, and also to viruses having a fibre and hexon from Adll, including Adllp.
Brief Description of the Figures
Figure 1 Is an extract from Kamen and Henry 2004 (J Gene Med. 6: S184-192) showing a schematic diagram of the processes involved manufacture of the GMP grade adenovirus.
Figure 2 shows the proportion of infectious ColoAdl particles associated with the cells and
supernatant (SN) of suspension HEK293s infected at MOI 10.
Figure 3 shows the proportion of infectious ColoAdl particles associated with the cells and
supernatant (SN) of adherent HEK293s infected at MOI 10 (multiplicity of infection 10). Figure 4 shows total viral particle amounts of suspension HEK293 culture in an assay testing
infection condition.
Figure 5 Visualisation of cellular and viral DNA in the cell lysate (Lysate) or supernatant (SN) of
ColoAdl infected HEK293 cells at 40hrs, 46hrs and 70hrs post-infection
Figure 6 A - Virus distribution (CVL or supernatant),
B - Total virus production (vp/cell) and
C - Cell viability at each time point post-infection for ColoAdl.
Figure 7 A - Virus distribution (CVL or supernatant),
B - Total virus production (vp/cell) and
C - Cell viability at each time point post-infection for wild-type Ad5.
Figure 8 A - Virus distribution (CVL or supernatant),
B - Total virus production (vp/cell) and
C - Cell viability at each time point post-infection for wild-type Adllp.
Detailed Description of the Disclosure
Adenovirus as employed will generally refer to a replication competent adenovirus or replication deficient, for example a group B virus, in particular Adll, such as Adllp, unless the context indicates otherwise. In some instances it may be employed to refer only to replication competent viruses and this will be clear from the context.
Adenovirus vector will generally refer to a replication deficient adenovirus.
Subgroup B (group B or type B) as employed herein refers to viruses with at least the fibre and hexon from a group B adenovirus, for example the whole capsid from a group B virus, such as substantially the whole genome from a group B virus.
Enadenotucirev (EnAd) is a chimeric oncolytic adenovirus, formerly known as EnAd (WO2005/118825), with fibre, penton and hexon from Adllp, hence it is a subgroup B virus. It has a chimeric E2B region, which comprises DNA from Adllp and Ad3. Almost all of the E3 region and part of the E4 region is deleted in EnAd.
A process for the manufacture of an adenovirus as employed herein is intended to refer to a process wherein the virus is replicated and thus the number of viral particles is increased. In particular the manufacturing is to provide sufficient numbers of viral particles to formulate a therapeutic product, for example in the range 1-9 x 10s to 1-9 x 1020 or more particles may be produced, such as in the range of 1-9 xlO8 to 1-9 xlO15 viral particles, in particular 1 to 9 xlO10 or 1-9 x 1015 viral particles may be produced from a 10L batch.
Part of the E3 region is deleted (partly deleted in the E3 region) as employed herein refers to at least part, for example in the range 1 to 99% of the E3 region is deleted, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94 95, 96, 97 or 98% deleted, for example in a coding and/or non-coding region of the gene.
Completely deleted (also referred to herein as wholly deleted) in the E3 region means the coding part of the gene is completed deleted. In one embodiment the coding and non-coding part of the gene is deleted.
E3 as employed herein refers to the DNA sequence encoding part or all of an adenovirus E3 region (i.e. protein/polypeptide), it may be mutated such that the protein encoded by the E3 gene has conservative or non-conservative amino acid changes, such that it has the same function as wild-type (the corresponding unmutated protein); increased function in comparison to wild-type protein; decreased function, such as no function in comparison to wild-type protein or has a new function in comparison to wild-type protein or a combination of the same, as appropriate.
The viruses of the present disclosure are not partly deleted in the E4 region. In one embodiment the Eorf4 is not deleted.
Part of the E4 region is deleted (partly deleted in the E4 region) as employed herein means that at least part, for example in the range 1 to 99% of the E4 region is deleted, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94 95, 96, 97 or 98% deleted.
Completely present in the E4 region means the E4 is 100% present i.e. nothing is removed. Having said that the gene may be: mutated wherein up to 10% of the base pairs are replaced (but not deleted); or be interrupted, for example the E4 region may be interrupted by a transgene. Thus 100% complete as employed herein means 100% present in the relevant location in the genome, however the gene many be contiguous or non-contiguous.
Completely deleted (also referred to herein as wholly deleted) in the E4 region means the coding part of the gene is completed deleted. In one embodiment the coding and non-coding part of the gene is deleted.
E4 as employed herein refers to the DNA sequence encoding an adenovirus E4 region (i.e.
polypeptide/protein region), which may be mutated such that the protein encoded by the E4 gene has conservative or non-conservative amino acid changes, and has the same function as wild-type (the corresponding non-mutated protein); increased function in comparison to wild-type protein; decreased function, such as no function in comparison to wild-type protein or has a new function in comparison to wild-type protein or a combination of the same as appropriate.
The E4 region may have some function or functions relevant to viral replication and thus modifications, such as deletion of the E4 region may impact on a virus life-cycle and replication, for example such that a packaging cell may be required for replication.
"Derived from" as employed herein refers to, for example where a DNA fragment is taken from an adenovirus or corresponds to a sequence originally found in an adenovirus. This language is not intended to limit how the sequence was obtained, for example a sequence employed in a virus according to the present disclosure may be synthesised.
In one embodiment the derivative has 100% sequence identity over its full length to the original
DNA sequence.
In one embodiment the derivative has 95, 96, 97, 98 or 99% identity or similarity to the original DNA sequence.
In one embodiment the derivative hybridises under stringent conditions to the original DNA sequence.
As used herein, "stringency" typically occurs in a range from about Tm (melting temperature)- 50°C (5° below the Tm of the probe) to about 20°C to 25°C below Tm.- As will be understood by those of skill in the art, a stringent hybridization can be used to identify or detect identical polynucleotide sequences or to identify or detect similar or related polynucleotide sequences. As herein used, the term "stringent conditions" means hybridization will generally occur if there is at least 95%, such as at least 97% identity between the sequences.
As used herein, "hybridization" as used herein, shall include "any process by which a polynucleotide strand joins with a complementary strand through base pairing" (Coombs, J., Dictionary of Biotechnology, Stockton Press, New York, N.Y., 1994).
Wherein the isolation is not subsequent to a cell lysis step" as employed herein is intended to refer to the fact the manufacturing process does not comprise a specific lysis step. That is to say a step where the conditions are designed to lyse all or most of the cells in the culture, for example does not employ a chemical lysis step, an enzymatic lysis step, a lysis buffer step, a mechanical lysis step or a physical lysis step such as centrifuging or freeze-thawing.
Conditions of the culture that ultimately stress all the cells such that they die and lyse, for example starving the cells to death under batch culture conditions will be considered a specific lysis step in the context of the present specification.
Most as employed herein refers to a large majority, for example 50% or more such as 80, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%.
"At the end of the culturing period" as employed herein refers to at the end of a period over which the virus in the infected cells has been allowed to replicate. End refers to a selected point in time selected for harvesting. End as employed herein is not definitive end-point. In one embodiment the end- point is chosen to follow a sufficient period of cultivation for the replicated virus or a significant proportion thereof to be released into the medium or supernatant. In one embodiment the harvesting occurs at multiple time points or is ongoing after it is initiated.
Advantageously, the present process may simplify downstream processing of the virus because of the lower starting concentration of contaminating DNA from the cells because a cell lysis step is avoided. This may result in cost savings because reagents, equipment and time employed in downstream processing may be reduced. It may also result in greater purity with lower end concentrations of contaminating DNA and/or a lower concentration of large fragments of contaminating DNA.
Furthermore, virus exposure to cell enzymes is minimised by avoiding cell lysis, which minimises the exposure of the virus to potential degradants, such as nucleases from the cell. This may result in higher virus stability and/or potency as measured, for example by infectivity.
The use of benzonase to degrade cellular DNA may also be avoided or reduced if desired, which may be advantageous. In particular, removal of the benzonase and testing to show the absence of residual benzonase can be avoided.
Interestingly, after exiting the cells the virus of the present disclosure does not adhere to the cells and so can be readily recovered from the supernatant. This may be a phenomenon which is characteristic of the viruses described herein which facilitates the current process. In contrast, wild-type Ad5 is thought to adhere to cells. In fact, results have shown that substantially no wild-type Ad5, viral particles are present in the supernatant (see Figure 7 & table 6).
In one embodiment viruses of the present disclosure further comprise a transgene.
In one embodiment the lack of adherence to the cells may be related to the hexon and fibre of the virus.
Oncolytic viruses are those which preferentially infect cancer cells and hasten cell death, for example by lysis of same, or selectively replicate in the cancer cells. Viruses which preferentially infect cancer cells are viruses which show a higher rate of infecting cancer cells when compared to normal healthy cells.
In one embodiment the virus of the present disclosure is chimeric, for example comprises genomic sequence from at least two adenovirus subgroups excluding subgroup A which is thought to be
cancer causing. In one embodiment the chimeric adenoviruses of the present disclosure are not chimeric in the E2B region.
A adenoviruses such as chimeric adenovirus can be evaluated for its preference for a specific tumor type by examination of its lytic potential in a panel of tumor cells, for example colon tumor cell lines include HT-29, DLD-1, LS174T, LS1034, SW403, HCT116, SW48, and Colo320DM. Any available colon tumor cell lines would be equally useful for such an evaluation.
Prostate cell lines include DU145 and PC-3 cells. Pancreatic cell lines include Panc-1 cells. Breast tumor cell lines include MDA231 cell line and ovarian cell lines include the OVCA -3 cell line. Hemopoietic cell lines include, but are not limited to, the Raji and Daudi B-lymphoid cells, K562 erythroblastoid cells, U937 myeloid cells, and HSB2 T-lymphoid cells. Other available tumor cell lines are equally useful.
In one embodiment a virus of the present disclosure is oncolytic. Oncolytic viruses including those which are non-chimeric (i.e. oncolytic viruses may be chimeric or non-chimeric), for example Adll, such as Adllp can similarly be evaluated in these cell lines and has oncolytic activity.
Viruses which selectively replicate in cancer cells are those which require a gene or protein which is upregulated in a cancer cell to replicate, such as a p53 gene.
In one embodiment the oncolytic virus of the present disclosure is apoptotic, that is hastens programmed cell death. In one embodiment the oncolytic virus of the present disclosure is cytolytic. The cytolytic activity of chimeric oncolytic adenoviruses of the disclosure can be determined in representative tumor cell lines and the data converted to a measurement of potency, for example with an adenovirus belonging to subgroup C, preferably Ad5, being used as a standard (i.e. given a potency of 1). A suitable method for determining cytolytic activity is an MTS assay (see Example 4, Figure 2 of WO 2005/118825 incorporated herein by reference). In one embodiment the oncolytic adenovirus of the present disclosure causes cell necrosis.
In one embodiment the chimeric oncolytic virus has an enhanced therapeutic index for cancer cells. Therapeutic index" or "therapeutic window" refers to a number indicating the oncolytic potential of a given adenovirus which may be determined by dividing the potency of an oncolytic adenovirus of the present disclosure in a relevant cancer cell line by the potency of the same adenovirus in a normal (i.e. non-cancerous) cell line. In one embodiment the oncolytic virus has an enhanced therapeutic index in one or more cancer cells selected from the group comprising colon cancer cells, breast cancer cells, head and neck cancers, pancreatic cancer cells, ovarian cancer cells, hemopoietic tumor cells, leukemic cells, glioma cells, prostate cancer cells, lung cancer cells, melanoma cells, sarcoma cells, liver cancer cells, renal cancer cells, bladder cancer cells and metastatic cancer cells.
There are currently about 56 adenovirus serotypes. Table 1 shows the adenovirus serotypes:
Subgroup Adenoviral Serotype
A 12, 18, 31
B 3, 7, 11, 14, 16, 21, 34, 35, 50, 55
C 1, 2, 5, 6
D 8-10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39, 42-51, 53, 54, 56
E 4
F 40, 41
G 52
The E2B region is a known region in adenoviruses and represents about 18% of the viral genome. It is thought to encode protein IVa2, DNA polymerase and terminal protein. In the Slobitski strain of Adll (referred to as Adllp) these proteins are encoded at positions 5588-3964, 8435-5067 and 10342-8438 respectively in the genomic sequence and the E2B region runs from 10342-3950. The exact position of the E2B region may change in other serotypes but the function is conserved in all human adenovirus genomes examined to date as they all have the same general organisation.
In one embodiment the virus of the present disclosure, such as an oncolytic virus has a subgroup B hexon.
In one embodiment the virus of the disclosure, such as an oncolytic virus has an Adll hexon, such as an Allp hexon. In one embodiment the virus of the disclosure, such as an oncolytic virus has a subgroup B fibre. In one the virus of the disclosure, such as an oncolytic virus has an Adll fibre, such as an Allp fibre. In one embodiment the virus of the disclosure, such as an oncolytic virus has fibre and hexon proteins from the same serotype, for example a subgroup B adenovirus, such as Adll, in particular Adllp.
In one embodiment the virus of the disclosure, such as an oncolytic virus has fibre, hexon and penton proteins from the same serotype, for example Adll, in particular Adllp, for example found at positions 30811-31788, 18254-21100 and 13682-15367 of the genomic sequence of the latter.
A virus of a distinct serotype to a first virus may be from the same subgroup or a different subgroup but will always be from a different serotype. In one embodiment the combinations are as follows in (first Ad serotype: second Ad serotype): AA, AB, AC, AD, AE, AF, AG, BB, BC, BD, BF, BG, CC, CD, CE, CF, CG, DD, DE, DF, DG, EE, EF, EG, FF, FG and GG.
Mammalian cells are cell derived from a mammal. In one embodiment the mammalian cells are selected from the group comprising HEK, CHO, COS-7, HeLa, Viro, A549, PerC6 and GM K, in particular H EK293.
Replication deficient viruses of the present disclosure require a packaging cell line to replicate.
Packaging cell lines contain a gene or genes to complement those which are deficient in the virus.
In one embodiment the cells are grown in adherent or suspension culture, in particular a suspension culture.
Culturing mammalian cells as employed herein refers to the process where cells are grown under controlled conditions ex vivo. Suitable conditions are known to those in the art and may include temperatures such as 37°C. The C02 levels may need to be controlled, for example kept at a level of 5%.
Details of the same are given in the text Culture of Animal Cells: A Manual of Basic Techniques and
Specialised Applications Edition Six R. Ian Freshney, Basic Cell Culture (Practical Approach) Second
Edition Edited by J.M. Davis.
Usually the cells will be cultured to generate sufficient numbers before infection with the adenovirus. These methods are known to those skilled in the art or are readily available in published protocols or the literature.
Generally the cells will be cultured on a commercial scale, for example 5L, 10L, 15L, 20L, 25L,
30L, 35L, 40L, 45L, 50L, 100L, 200L, 300L, 400L, 500L, 600L, 700L, 800L, 900, 1000L or similar.
Media suitable for culturing mammalian cells include but are not limited to EX-CELL® media from Sigma-Aldrich, such as EX-CELL®293 serum free medium for HEK293 cells, EX-CELL® ACF CHO media serum free media for CHO cells, EX-CELL® 302 serum free media for CHO cells, EX-CELL CD hydrolysate
fusion media supplement, from Lonza RMPI (such as RMPI 1640 with HEPES and L-glutamine, RMPI 1640 with or without L-glutamine, and RMPI 1640 with UltraGlutamine), MEM and DMEM, SFMII medium.
In one embodiment the medium is serum free. This is advantageous because it facilitates registration of the manufacturing process with the regulatory authorities.
The viruses of the present disclosure, such as oncolytic viruses have different properties to those of adenoviruses used as vectors such as Ad5, this includes the fact that they can be recovered from the medium without the need for cell lysis. Thus, whilst not wishing to be bound by theory, the viruses appear to have mechanisms to exit the cell.
In one embodiment the group viruses employed in the method of the present disclosure appear much earlier in the supernatant than group C adenoviruses, in particular Ad5, under corresponding conditions.
In one embodiment the viruses employed in the method of the present disclosure are available in the supernatant at a given time point, for example in the range of 30 to 100 hours at levels which exceed the levels of achieved for group C viruses, such as Ad5 under corresponding conditions.
Furthermore, the viruses of the present disclosure, such as oncolytic adenoviruses do not seem to associate or adhere the cells after exiting the same, which also facilitates recovery from the supernatant, in particular when the cell culturing conditions are optimised.
In addition the viruses of the present disclosure do not appear to degrade, even when the culturing process is extended to 70 hours or more. The degradation of the virus can be checked by assaying the infectivity of the virus. The infectivity of the virus decreases as the viral particles degrade.
In one embodiment the culturing period is in the range 30 to 100 hours, for example 35 to 70 hours, for example 40, 45, 50, 55, 60 or 65 hours.
In one embodiment the culturing period is 65, 70, 75, 80, 85, 90, 95 hours or more.
In one embodiment the culturing period is in the range 60 to 96 hours.
In one embodiment over 90% of the group B adenovirus is present in the supernatant at the 64 hour time point, for example, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100%, such as 95% or more, particularly 98% or more.
In one embodiment significant amounts of virus are in media post 38 hours. For example, over 50%, particularly over 70% of the virus is in the media post 38 hours.
In one embodiment the maximum total virus production is achieved at about 40 to 60 hours post-infection, for example 49 hours post-infection. In one embodiment the decrease in virus production following the maximum is slow.
In one embodiment the maximum total virus production is achieved at about 60 to 96 hours, for example 70 to 90 hours post-infection.
Surprisingly, the present inventors have found that, when employing the process, the cells maintain high viability (such as 80 to 90% viability) post-infection for over 90 hours. Thus in one embodiment the harvesting and process may continue as long as the cells remain viable.
Maximum total virus production as employed herein means the total number of viral particles produced per cell and encompasses viral particles in the supernatant and the cell.
In one embodiment the virus production in the supernatant at 49 hours post-infection is about
20000 to 30000 viral particles per cell (vp/cell). For example 26000 vp/cell.
In one embodiment there is less than 10% detectable virus in the CVL pellet at the 64 hour time point, i.e. post 64 hours, such as 9, 8, 7, 6, 5, 4, 3, 2, 1% detectable virus. Example 6 describes how the CVL was obtained.
CVL as employed herein means the crude viral lysate.
Culturing cells may employ a perfusion culture, fed batch culture, batch culture, a steady state culture, a continuous culture or a combination of one or more of the same as technically appropriate, in particular a perfusion culture.
In one embodiment the process is a perfusion process, for example a continuous perfusion process.
In one embodiment the culture process comprises one or more media changes. This may be beneficial for optimising cell growth, yield or similar. Where a medium change is employed, it may be necessary to recover virus particle from the media being changed. These particles can be combined with the main virus batch to ensure the yield of virus is optimised. Similar techniques may also be employed with the medium of a perfusion process to optimise virus recovery.
In one embodiment the culture process does not include a medium change step. This may be advantageous because no viral particles will be lost and therefore yield may be optimised.
In one embodiment the culture process comprises one or more cell additions or changes. Cell addition as employed herein refers to replenishing some or all of the cells and change refers to removing dead cells and adding new cells (not necessarily in that order).
In one embodiment the adenovirus during culture is at concentration in the range 20 to 150 particles per cell (ppc), such as 40 to 100 ppc, in particular 50ppc.
Lower values of virus concentrations, such as less than lOOppc, in particular 50ppc may be advantageous because this may result in increased cell viability compared to cultures with higher virus concentrations, particularly when cell viability is measured before harvesting.
Low cell viability can result in cell lysis which may expose the cell to enzymes, which with time may attack the virus. However, in a dynamic process such as cell culturing a percentage, usually a small percentage of cells may be unviable. This does not generally cause significant problems in practice.
In one embodiment cell viability is around 80 to 95% during the process, for example at the 96 hour time point (i.e. 96 hours post-infection) when infected with virus, such as 83 to 90% viability.
In one embodiment cell viability is around 80 to 90% during the process, for example at the 96 hour time point (i.e. 96 hours post-infection) when infected with Adll. For example 85% viability.
In one embodiment the medium and/or cells are supplements or replenished periodically.
In one embodiment the cells are harvested during the process, for example at a discrete time point or time points or continuously.
In one embodiment harvesting the virus is performed at a time point selected from about 40,
46, 49, 64, 70, 73, 89 or 96 hours post infection or a combination thereof.
In one embodiment of the process the mammalian cells are infected with a starting concentration of virus of 1-9 x 104 vp/ml or greater, such as 1-9 x 10s, 1-9 x 10s, 1-9 x 107, 1-9 x 10s, 1-9 x 109, in particular 1-5 x 10s vp/ml or 2.5-5 x 10s vp/ml.
In one embodiment of the process the mammalian cells are infected at a starting concentration of 1x10s cells/ml at about 1 to 200ppc, for example 40 to 120ppc, such as 50ppc.
Ppc as employed herein refers to the number of viral particles per cell.
In one embodiment the process is run at about 35 to 39°C, for example 37°C.
In one embodiment the process run at about 4-6% C02, for example 5% CO2.
In one embodiment the media containing the virus, such as the chimeric oncolytic viral particles is filtered to remove the cells and provide crude supernatant for further downstream processing. In one embodiment a tangential flow filter is employed.
In one embodiment medium is filtered employing Millipore's Millistak+® POD system with cellulose based depth filters. Millistak+® depth filter medium is offered in a scalable, disposable format, the Pod Filter System. It is ideal for a wide variety of primary and secondary clarification applications, including cell cultures.
Millistak+® Pod filters are available in three distinct series of media grades in order to meet specific application needs. Millistak+® DE, CE and HC media deliver optimal performance through gradient density matrix as well as positive surface charge properties. In one embodiment the filtration is effected using tangential flow technology, for example employing the Cogent™ M system comprising a Pellicon Mini cassette membrane holder, pressure sensors, 10 litre recycle tank with mixer, retentate flow meter, weigh scale, feed pump, transfer pump, piping and valves. Control and operation of the system is manual with an exception of semi-automatic diafiltration/concentration. The operator has manual control of pump speeds, all valves and operational procedures. The virus can also, if desired, be formulated into the final buffer in this step.
Thus in one embodiment in the filtration step, concentrated and conditioned adenovirus material is provided in a final or near final formulation.
In one embodiment the process comprises two or more filtration steps.
In one embodiment the downstream processing comprises Millistak+POD system 35 CE and 50 CE cassettes followed by an opticap XL 10 express 0.5/0.2 um membrane filter in series.
In one embodiment the process further comprises a purification step, selected from a CsCI gradient, chromatography step (such as size exclusion chromatography), ion-exchange chromatography (in particular anion-exchange chromatography) and a combination thereof.
Ion exchange chromatography binds DNA very strongly and typically is the place were any residual DNA is removed. The ion exchange resin/membrane binds both the virus and the DNA and during salt gradient elusion the virus normally elutes off the column first (low salt gradient) and the DNA is eluted at a much higher salt concentration since the interaction of the DNA with the resin is stronger than the virus.
In one embodiment the chromatography step or steps employ monolith technology, for example available from BIA Separations. In one embodiment Sartobind Q (quaternary amine membrane purification process) is employed as a purification step. In one embodiment Source Q RESIN is employed in a purification step. In one embodiment Sartobind Q is employed followed by Source Q RESIN in downstream processing of the isolated virus. In one embodiment Source Q is employed in the purification step.
In one embodiment after purification the virus prepared contains less than 80ng/mL of contaminating DNA, for example between 60ng/mL and lOng/mL.
In one embodiment substantially all the contaminating DNA fragments are 700 base pairs or less, for example 500bp or less, such as 200bp or less.
In one embodiment residual benzonase content in the purified virus product is Ing/mL or less, such as 0.5ng/mL or less.
In one embodiment the residual host cell protein content in the purified virus product in 20ng/mL or less, for example 15ng/mL or less, in particular when measured by an ELISA assay.
In one embodiment residual tween in the purified virus product is O.lmg/mL or less, such as
0.05mg/mL or less.
In one embodiment the virus has a hexon and fibre from a group B adenovirus, for example
Ad 11.
In one embodiment there is provided isolated purified group B adenovirus according to the present disclosure wherein the contaminating DNA content is less than 80ng/mL.
In one embodiment the virus is replication competent. Replication competent virus as employed herein refers to a virus that is capable of replication without the assistance of a complementary cell line encoding an essential viral protein, such as that encoded by the El region (also referred to as a packaging cell line) and virus capable of replicating without the assistance of a helper virus.
Viral vectors are replication deficient and require a packaging cell to provide a complementary gene to allow replication.
In one embodiment the virus of the disclosure, such as an oncolytic virus of the present disclosure comprises one or more transgenes, for example one or more transgenes encoding therapeutic peptide(s) or protein sequence(s).
In one embodiment a virus such as an oncolytic virus encodes at least one transgene. Suitable transgenes include so called suicide genes such as p53; polynucleotide sequences encoding cytokines such as IL-2, IL-6, IL-7, IL-12, IL-15, IL-18, IL-21, GM-CSF or G-CSF, an interferon (eg interferon I such as IFN-alpha or beta, interfon II such as IFN-gamma), a TNF (eg TNF-alpha or TNF-beta), TGF-beta, CD22, CD27, CD30, CD40, CD120; a polynucleotide encoding a monoclonal antibody, for example trastuzamab, cetuximab, panitumumab, pertuzumab, epratuzumab, an anti-EGF antibody, an anti-VEGF antibody and anti-PDGF antibody, an anti-FGF antibody.
A range of different types of transgenes, and combinations thereof, are envisaged that encode molecules that themselves act to modulate tumour or immune responses and act therapeutically, or are agents that directly or indirectly inhibit, activate or enhance the activity of such molecules. Such molecules include protein ligands or active binding fragments of ligands, antibodies (full length or fragments, such as Fv, ScFv, Fab, F(ab)'2 or smaller specific binding fragments), or other target-specific binding proteins or peptides (e.g. as may be selected by techniques such as phage display etc), natural or synthetic binding receptors, ligands or fragments, specific molecules regulating the transcription or translation of genes encoding the targets (e.g. siRNA or shRNA molecules, transcription factors). Molecules may be in the form of fusion proteins with other peptide sequences to enhance their activity, stability, specificity etc (e.g. ligands may be fused with immunoglobulin Fc regions to form dimers and enhance stability, fused to antibodies or antibody fragments having specificity to antigen presenting cells such as dendritic cells (e.g. anti-DEC-205, anti-mannose receptor, anti-dectin). Transgenes may also encode reporter genes that can be used, for example, for detection of cells infected with the "insert- bearing adenovirus", imaging of tumours or draining lymphatics and lymph nodes etc.
In one embodiment the cancer cell infected with an oncolytic virus is lysed releasing the contents of the cell which may include the protein encoded by a transgene.
In one embodiment 40 to 93% or more of the total virus replicated in the cells is recoverable from the media, for example 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 or 92% of the total virus is recoverable, such as 94, 95, 96, 97, 98, 99 or 100% of the total virus recoverable.
In one embodiment the process is a GMP manufacturing process, such as a cGMP manufacturing process. In one embodiment the process further comprises the step formulating the virus in a buffer suitable for storage. In one embodiment the present disclosure extends to virus or viral formulations obtained or obtainable from the present method.
Known methods for cell lysis include employing lysis buffer (pH 8.0) containing MgCI2 and detergent, e.g. 1% Tween-20. Cell lysis is performed without pH or p02 controls. Rocking and heating are used. Lysis is continued for 1.5-2 hours.
Freeze-thawing multiple times is also a routine method of cell lysis. Pulmozyme may also be employed in cell lysis. Alternative methods for cell lysis include centrifuging cell suspension at 1000 x g, 10 min at 4 °C. Resuspending the cell pellet into 1 ml of Ex-Cell medium 5 % glycerol and releasing the viruses from the cells by freeze-thaw by freezing tubes containing the responded cells from the pellet in liquid nitrogen for 3 - 5 minutes and thaw at +37°C water bath until thawed. Generally the freeze and thaw step is repeated twice more. This cycle releases viruses from the cells. After the last thaw step remove the cell debris by centrifugation 1936 x g, 20 min at +4 °C.
Benzonase (Merck), 100 U/ml, is used to digest host cell DNA. Benzonase treatment is done for 30 min in +37 °C. Benzonase is stopped with high salt incubation for 1 hour at RT.
In the context of the resent application, medium and media may be used interchangeably. In the context of this specification "comprising" is to be interpreted as "including". Aspects of the invention comprising certain elements are also intended to extend to alternative embodiments "consisting" or "consisting essentially" of the relevant elements. Where technically appropriate, embodiments of the invention may be combined. Embodiments are described herein as comprising certain features/elements. The disclosure also extends to separate embodiments consisting or consisting essentially of said features/elements. Technical references such as patents and applications are incorporated herein by reference. Any embodiments specifically and explicitly recited herein may form the basis of a disclaimer either alone or in combination with one or more further embodiments.
The present invention is further described by way of illustration only in the following examples.
EXAMPLES
Example 1 Suspension HEK293s (1 x 10s cells/mL in 125mL shake flasks at lOOrpm) were infected at MOI 10 and fed with CD293 media 2 hours after infection with EnAd (ColoAdl). Samples were taken 6, 24, 30, 48, 54 and 78 hours after infection. The supernatant was separated from the cells by centrifugation and the cell pellet resuspended in cell lysis buffer. The amount of infectious EnAd particles in the cells and supernatant were determined by immunostaining infectivity assay and expressed as a proportion of the total at each time point. N = 1, error bars (SD) show triplicate infections. Results are shown in Figure 2.
Example 2 Adherent HEK293s (1 x 106cells/mL in lmL of 24-well plate) were infected at MOI 10 (in 2% FCS containing media). At 6, 24, 30, 48, 54, 72 and 78 hours after infection with EnAd supernatant was removed, and cells detached from the surface before re-suspending in cell lysis buffer. The amount of infectious EnAd particles associated with the cells and supernatant were determined by immunostaining infectivity assay and expressed as a proportion of the total at each time point. N = 1, error bars (SD) show triplicate infections. Results shown in Figure 3.
Example 3 EnAd cultured in a HEK 293 suspension culture
Infection conditions for oncolytic virus EnAd were tested in a small scale suspension HEK293 culture.
Cells were cultured for 96 hours prior to infection using Ex-Cell - 6 mM L-glutamine - 50 g/ml/50 lU/ml Penicllin/Streptomycin at +37 °C and 5% C02.
Cell counting was performed using Burker cell hemacytometer and Trypan Blue stain (Invitrogen, 15250-
061). For larger dilutions (dilution factor 3 or greater) cell culture medium with Trypan blue was used.
Two virus dilutions (50 and 100 particles per cell) and six harvesting time points (40, 43, 36, 49, 64, and
70 h) were tested. All the testing was done in duplicate shaker flasks. The viral particle concentrations of the samples were analysed with AEX-HPLC and the results are shown in Tables 3 and 4.
Table 3. AEX-HPLC results of the cell samples (intracellular virus cone) of suspension HEK239 culture in infection condition testing.
Table 4. AEX-HPLC results of the medium samples and total intracellular and extracellular virus amount of suspension HEK239 culture in infection condition testing.
The highest amount of viral particles was produced when infecting the cells for 70 hours with 100 ppc (the average results of duplicate flasks 1.05E+13vp, Table 4). At that time point, 93 % of the viral particles were in the medium. It can be seen from Figure 5, that the total amount of virus increased up to 70 hours, but the curve seemed to start approaching plateu after 64 hours. Already at 43 hours, over half of the virus is in the culture medium, however, in the suspension production process, also the viral particles in the medium can be captured during purification. In 70 hours, MOI of 100 ppc produced 2.6E+12 more viral particles than 50 ppc (and 2.8E+12 more in 64 h). But even with 50 ppc, the production capacity of the cells appeared to be close to the maximum: the intracellular virus amount remained fairly constant during the time range of 40-70 hours.
Example 4 En Ad cultured in adherent HEK 293 cells
Adherent HEK293 cells were seeded at 4.8 x lOe cells per flask in 185 crri2 cell culture flasks (24 pieces) 72 hours prior to infection. Cell culturing was performed using DMEM - 10% FBS - 2 mM L-glutamine at +37 °C and 5% CO2. Cell number was counted from one cell culture flask on the day of infection resulting 40.6 x 10s cells / flask. The tested particles per cell (ppc) were 200, 100 and 50. After infection the cells may be cultured for between 35 to 70 hours.
Example 5 Visualisation of cellular and viral DNA in the cell lysate (Lysate) or supernatant (SN) of EnAd infected HEK293 cells at 40hrs, 46hrs and 70hrs post-infection.
HEK293 cells infected with EnAd at 50 particles per cell were harvested 40 hours, 46 hours or 70 hours post-infection. The culture supernatants and the cell lysates were collected and total DNA extracted. Equivalent volumes of purified lysate or supernatant DNA were loaded in duplicate onto a 0.7% agarose gel and the DNA was separated electrophoresis. Significant cellular DNA could be detected at the top of the gel and as a smear in all lanes containing DNA extracted from cell lysates, however only very low levels of cellular DNA could be detected in lanes containing DNA extracted from supernatant (SN). In contrast, viral DNA could be detected in all samples and the total detectable viral DNA observably increased in the supernatant over time. Results are shown in Figure 5.
Example 6
EnAd and Adllp (referred to in the figures and tables as Adll) were compared for the relative levels of expression of virus particles associated with the cell pellet (CVL) or in the supernatant.
Table 5. Total adenoviral particle concentration of virus (by HPLC assa
Suspension HEK293 cells (293f) were cultured in duplicate shaker flasks containing 40 ml working volume of SFMII media supplemented with 4 mM L-glutamine and 50 μg/ml/50 lU/ml
Penicillin/Streptomycin and infected at 10s cells/ml with viruses at a ratio of 50 virus particles per cell (ppc).
The cell expansion was started by thawing one vial of cells and continued cell expansion for 3 weeks until a total of 4.8 x 10s cells required for this study was achieved. Three days before infection, the HEK 293 suspension cells were seeded in a single one litre shaker flask using 4 x 10s cells/ml in 428 ml of SFMII medium per flask (3.4 x 10s cells/ flask) and incubated in a shaker incubator at + 37°C, 5 % CO2 &115 rpm.
On the day of infection the cell count was performed and based on cell density, 225 ml of cell suspension at 2.15 x 10s cell/ml was used for the study. Remaining cells were discarded.
HEK 293 suspension cells were infected with one of the four different viruses (see Table 5 ) at 50 ppc in duplicate.
A 1:100 dilution of each virus was performed in SFMII growth medium prior to infection of cells (for virus concentration refer to Table 5).
Table 6. Infection calculation and dilution of virus prior to infection
Infection of suspension HEK293 cells with virus diluted as follows:
225 ml of cell suspension at 2.15 x 10s was centrifuged and the cell pellets was resuspended in 480 ml media to adjust the cell concentration to lx 10s cells/ml,
Thereafter, 10 shaker flasks with working volume of 40 ml per shaker flask were prepared. Dual flask were labelled as ColoAdl-AlA2, Ad5-D1D2 and AdllElE2 respectively.
All labelled flasks were infected with 50 ppc virus in accordance with Table 6.
All shaker flasks were placed in a shaking incubator at + 37°C, 5 % CO2 &120 rpm until harvested.
At 40, 46, 49, 64, 70, 73 and 89 hours post infection, 2.5ml samples were taken from each flask and the duplicates pooled to provide 5.0ml samples. At 96 hours post-infection, all the cells were harvested. Cell viabilities were assessed using 0.5ml and the remaining 4.5ml volume was then centrifuged and the virus distribution between the supernatant and cell pellet for each virus was determined in the following way:
The cells were centrifuged at 1000 x g, 10 min at 4 °C
After centrifugation, the supernatant was gently poured into a sterile container and 0.5 ml of 50% glycerol was added to the sample 1ml aliquots were stored at -80°C until analysis.
The cell pellet was suspended in 1ml of SFMII medium containing 5% glycerol,
Intracellular virus was released from the cells by freeze-thaw as follows:
The centrifuge tubes were frozen in liquid nitrogen for 3-5 minutes and then transferred to a water bath set at +37°C until thawed.
The freeze and thaw process was repeated twice more as described in step a, above.
After the final thaw step, the cell debris is removed from the crude viral lysate (CVL) by centrifugation at 1936 x g for 20 min at +4°C and transfer of the supernatant (CVL) to a new container.
The CVL was aliquoted as 100 μΙ samples and stored at -80°C until analysis.
Total viral particle concentration (vp) from Crude Viral Lysate (CVL) and supernatant (SN) samples were analysed by AEX-HPLC assay. These values were then used to calculate the total number of virus
particles per culture and the percentage in the SN and CVL for each sample time point. These are represented as bar graphs, together with the viability of the HEK293 cells, for ColoAdl, Ad5 and Allp in Figs 6-8 respectively. For ColoAdl and Adllp the majority of virus was in the culture supernatant whereas for Ad5 virus was entirely in the cell lysate (CVL), being undetectable in the supernatant. For all cultures, the viability of the HEK293 cells remained high over the 96 hours of culture.
For EnAd (Figure 6 A), 84 % was present in the supernatant at 40hrs timepoint, and 98% present in the supernatant at 64h timepoint with no detectable virus in the CVL (pellet) sample.
For Adll (Figure 10A), 31 % of the virus was present in the supernatant at 40hrs timepoint, 88% present in the supernatant at 64h timepoint and 98% of the virus present in the supernatant at 96h timepoint, respectively.
For Ad5 (Figure 9A), 100 % of the virus was detected in CVL (pellet) sample with no virus detected in the supernatant.
For all viruses assessed in this study, the maximum level of virus was observed at 49 hrs post infection and there was a slow decrease in virus level observed thereafter in subsequent timepoints
For ColoAdl (Figure 6B) maximum virus level (27000 vp/cell) was observed at 49hrs timepoint.
For Ad5 (Figure 7B) the maximum virus level(11000 vp/cell) was observed at 89 hrs timepoint while in Adllp (Figure 8B) the maximum virus level (30000 vp/cell) was observed at same timepoint.
The total viral particle concentrations of all the supernatant and CVL samples analysed with AEX- HPLC are shown in Tables 7 and 8 and in Figures 6-8.
Table 7. AEX-HPLC assay results of ColoAdl
22
Claims
1. A process for the manufacture of adenovirus having a fibre and hexon of subgroup B (such as Adll, in particular Adllp also known as the Slobitski strain) wherein the E4 region completely present or completely deleted said process comprises the steps:
a. culturing mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and
b. at the end of the culturing period isolating from the media the virus from step a) by filtering wherein the isolation of virus is not subsequent to a cell lysis step.
2. A process according to claim 1, wherein the virus has a capsid from a group B adenovirus, for example Adll.
3. A process according to claim 1 or 2, wherein the virus is replication competent.
4. A process according to any one of claims 1 to 3, wherein the culturing period is in the range 30 to 100 hours, for example 35 to 70 hours.
5. A process according to any one of claims 1 to 4, wherein the culturing comprises a perfusion culture step, fed batch, batch, in particular a perfusion culture step.
6. A process according to any one of claims 1 to 5, wherein the cells are grown in adherent or suspension culture, in particular a suspension culture.
7. A process according to any one of claims 1 to 6, wherein the mammalian cells are selected from the group comprising HEK, CHO, HeLa, Viro, PerC6 and GMK, in particular HEK293.
8. A process according to any one of claims 1 to 7, wherein the culture is a scale of 5L or more.
9. A process according to any one of claims 1 to 8, wherein virus during culture is at concentration in the range 40 to 150 ppc, such as 50 to 100 ppc.
10. A process according to any one of claims 1 to 9, wherein the cells are infected with a starting concentration of virus of 1-9 x 104 vp/ml or greater, such as 1-9 x 10s, 1-9 x 10s, 1-9 x 107, 1-9 x 10s, 1-9 x 109, in particular 4 to 5 x 10s vp/ml.
11. A processes according to any one of claims 1 to 10, provides a fraction of virus wherein the process comprises a further step such that a second fraction or fractions of the virus made by the same of a different process is/are combined with the first fraction.
12 A process according to any one of claims 1 to 11, wherein the process is a GMP manufacturing process.
13. A process according to any one of claims 1 to 12, wherein the filter is a tangential filter.
14. A process according to any one of claims 1 to 13, wherein the process further comprises a
purification step, selected from a CsCI gradient, chromatography step such as ion-exchange chromatography in particular anion-exchange chromatography, and a combination thereof.
15. A process according to any one of claims 1 to 14, wherein 40 to 93 % of the total virus is
recoverable from the media.
16. A process according to any one of claims 1 to 15, which further comprises formulating the virus in a buffer suitable for storage.
17. A virus or formulation obtained or obtainable from this process described in any one of claims 1 to 16.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/121,758 US20170073647A1 (en) | 2014-02-28 | 2015-02-27 | Process for the preparation of group b adenoviruses |
EP15712073.4A EP3110431A1 (en) | 2014-02-28 | 2015-02-27 | A process for the preparation of group b adenoviruses |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2014/053987 WO2014131898A1 (en) | 2013-02-28 | 2014-02-28 | A process for the production of adenovirus |
EPPCT/EP2014/053987 | 2014-02-28 | ||
GB1415579.0 | 2014-09-03 | ||
GBGB1415579.0A GB201415579D0 (en) | 2014-09-03 | 2014-09-03 | A process |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015128500A1 true WO2015128500A1 (en) | 2015-09-03 |
Family
ID=51752541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2015/054219 WO2015128500A1 (en) | 2014-02-28 | 2015-02-27 | A process for the preparation of group b adenoviruses |
Country Status (4)
Country | Link |
---|---|
US (1) | US20170073647A1 (en) |
EP (1) | EP3110431A1 (en) |
GB (1) | GB201415579D0 (en) |
WO (1) | WO2015128500A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102089121B1 (en) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Oncolytic adenovirus compositions |
CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
CN108699566B (en) | 2016-02-23 | 2023-06-30 | 萨克生物研究学院 | Treatment of exogenous gene expression in adenoviruses with minimal effect on viral kinetics |
EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005118825A2 (en) | 2004-05-26 | 2005-12-15 | Schering Aktiengesellschaft | Chimeric adenoviruses for use in cancer treatment |
US20050287657A1 (en) * | 1996-07-01 | 2005-12-29 | Centelion | Method for producing recombinant adenovirus |
WO2008080003A2 (en) * | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
CN101235365A (en) * | 2007-01-31 | 2008-08-06 | 深圳市清华源兴生物医药科技有限公司 | Highly effective method for producing adenovirus |
WO2011045381A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005063970A1 (en) * | 2003-12-23 | 2005-07-14 | Schering Corporation | Methods for producing a549 cell lines stable in serum-free medium suspension culture |
RU2015135473A (en) * | 2013-02-28 | 2017-03-31 | Псайоксус Терапьютикс Лимитед | METHOD FOR OBTAINING Adenovirus |
-
2014
- 2014-09-03 GB GBGB1415579.0A patent/GB201415579D0/en not_active Ceased
-
2015
- 2015-02-27 US US15/121,758 patent/US20170073647A1/en not_active Abandoned
- 2015-02-27 WO PCT/EP2015/054219 patent/WO2015128500A1/en active Application Filing
- 2015-02-27 EP EP15712073.4A patent/EP3110431A1/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050287657A1 (en) * | 1996-07-01 | 2005-12-29 | Centelion | Method for producing recombinant adenovirus |
WO2005118825A2 (en) | 2004-05-26 | 2005-12-15 | Schering Aktiengesellschaft | Chimeric adenoviruses for use in cancer treatment |
WO2008080003A2 (en) * | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
CN101235365A (en) * | 2007-01-31 | 2008-08-06 | 深圳市清华源兴生物医药科技有限公司 | Highly effective method for producing adenovirus |
WO2011045381A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
Non-Patent Citations (6)
Title |
---|
COOMBS, J.: "Dictionary of Biotechnology", 1994, STOCKTON PRESS |
KAMEN; HENRY, J GENE MED., vol. 6, 2004, pages 184 - 192 |
KUHN IRENE ET AL: "Directed evolution generates a novel oncolytic virus for the treatment of colon cancer", PLOS ONE, vol. 3, no. 6, 18 June 2008 (2008-06-18), pages e2409/1 - e2409/11, XP009107025, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0002409 * |
R. IAN FRESHNEY: "Basic Cell Culture (Practical Approach", article "Culture of Animal Cells: A Manual of Basic Techniques and Specialised Applications" |
See also references of EP3110431A1 * |
STONE D ET AL: "THE COMPLETE NUCLEOTIDE SEQUENCE, GENOME ORGANIZATION, AND ORIGIN OF HUMAN ADENOVIRUS TYPE 11", VIROLOGY, vol. 309, no. 1, 25 April 2003 (2003-04-25), pages 152 - 165, XP001153788, ISSN: 0042-6822, DOI: 10.1016/S0042-6822(02)00085-5 * |
Also Published As
Publication number | Publication date |
---|---|
EP3110431A1 (en) | 2017-01-04 |
GB201415579D0 (en) | 2014-10-15 |
US20170073647A1 (en) | 2017-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2961417A1 (en) | A process for the production of adenovirus | |
US20170313990A1 (en) | A process for the production of adenovirus | |
CN102203242B (en) | Method for the production of adenoviral vectors | |
CA2841831C (en) | Methods and compositions for production of vaccinia virus | |
JP5250155B2 (en) | Method for producing Ad26 adenovirus vector | |
JP6009357B2 (en) | Method for producing adenovirus vector and virus preparation produced thereby | |
Sviben et al. | Recovery of infective virus particles in ion-exchange and hydrophobic interaction monolith chromatography is influenced by particle charge and total-to-infective particle ratio | |
WO2015128500A1 (en) | A process for the preparation of group b adenoviruses | |
KR20230118619A (en) | Adenovirus purification method | |
Davydova et al. | Oncolytic adenoviruses: design, generation, and experimental procedures | |
US20240033345A1 (en) | Method for producing virus | |
JP2023552472A (en) | How to produce adenovirus | |
CA3136313A1 (en) | Adenoviral polypeptide ix increases adenoviral gene therapy vector productivity and infectivity | |
CA3142628A1 (en) | Method of purifying a composition comprising a group b adenovirus | |
US11879139B1 (en) | Scalable methods for purification of recombinant viruses | |
KIRN et al. | Patent 2841831 Summary | |
KIRN et al. | Sommaire du brevet 2841831 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15712073 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15121758 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015712073 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015712073 Country of ref document: EP |